View Older Stories View More Recent Stories
-
Teva seeks clarity on Trump drug tariff plans, CEO says
-
Teva Pharma (TEVA) Misses Q2 EPS by 60c ; Offers Guidance
-
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
-
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
-
Teva lawsuit against Eli Lilly over Forteo revived by appeals court
-
Teva to advance vitiligo antibody TEV-'408 into Phase 2b trials
-
UBS Reiterates Buy Rating on Teva Pharma (TEVA) as Pipeline Opportunities Broaden
-
Teva submits NDA for ecopipam to treat pediatric Tourette syndrome
-
Immuneering reports 17.3-month survival in pancreatic cancer trial
-
Teva study reveals diagnostic gap in tardive dyskinesia among young adults
-
Immuneering reports Q1 2026 financial results and clinical updates
-
FDA greenlights continued generic access for Micardis
-
Teva Pharma (TEVA) PT Raised to $42 at UBS
-
Teva Pharma (TEVA) PT Lowered to $40 at BofA Securities
-
Teva Pharma (TEVA) PT Raised to $45 at Truist Securities
-
Teva Pharma (TEVA) PT Raised to $45 at Truist Securities
-
Teva Pharma (TEVA) Tops Q1 EPS by 5c; updates guidance
-
Teva Pharma (TEVA) PT Raised to $42 at BofA Securities
-
Jefferies on Teva Pharma (TEVA): 'early, but investors should pay attention'
-
Jefferies Reiterates Buy Rating on Teva Pharma (TEVA)
-
Barclays on Teva Pharma (TEVA) Amid 1.5pct Drop: '<$30 as a buy-the-dip oppty'
-
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
-
FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
-
There is 'much to be bullish about' this pharma stock: analyst
-
Teva Pharma (TEVA) PT Raised to $41 at Piper Sandler; 'Much To Be Bullish About'
-
FDA accepts Teva's drug application for monthly schizophrenia treatment
-
FDA accepts Teva's application for monthly schizophrenia injection
-
This stock looks cheap vs large-cap biopharma: Jefferies
-
Corcept loses patent appeal against Teva over generic Korlym
-
Corcept Therapeutics stock falls after losing key patent case appeal
-
Corcept Therapeutics (CORT) Drop Said Tied to Chatter it Lost Case Against Teva Pharma (TEVA)
-
Increasing unusual put option volume: GGAL FSLY FROG CENX XPO BK PINS AEVA WEN OKE TEVA
-
Teva Pharma (TEVA) PT Raised to $38 at Truist Securities
-
Teva Pharma (TEVA) PT Raised to $37 at BofA Securities
-
Teva Pharma (TEVA) Tops Q4 EPS by 31c, Beats on Revenue; Offers FY26 Revenue Guidance
-
Teva Pharma (TEVA) call put ratio 3.4 calls to 1 put into quarter results
-
Teva Pharma (TEVA) Gets FDA Ok For aNDA For Ferric Citrate Anhydrous
-
Teva's AJOVY reduces migraine days in children in clinical trial
-
Teva Pharma (TEVA) call put ratio 1 call to 1 put into updated guidance
-
Royalty Pharma provides up to $500 million for TEVA vitiligo drug
-
TEVA secures $500 million funding from Royalty Pharma for vitiligo drug
-
Teva Pharma (TEVA) call put ratio 6.3 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Jefferies just introduced this pharma stock as a top 2026 idea
-
Teva Pharma (TEVA) PT Raised to $37 at UBS
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
Teva Pharma (TEVA) PT Raised at Piper Sandler on Multiple Expansion Potential
-
Teva submits FDA application for monthly schizophrenia injection
-
Scotiabank Starts Teva Pharma (TEVA) at Sector Outperform
-
Bernstein on IRA pricing: $245 really is the floor
-
Teva receives European approvals for two denosumab biosimilars
